Search

A recent study published by the Student Research Committee highlights the case of a 69-year-old woman with Creutzfeldt-Jakob disease (CJD) who initially presented with parkinsonism, a rare symptom of the disease. The researchers emphasize the importance of early and accurate diagnosis of CJD to prevent misdiagnosis and optimize patient management. The study underscores the need for heightened clinical awareness of the uncommon initial presentations of CJD to prevent future misdiagnoses. Early diagnosis of CJD can also help prevent possible disease transmission and improve patient care. [Extracted from the article]

A new report from New York Medical College discusses the potential therapeutic value of beta-adrenergic agonists in Parkinson's disease. These agents may suppress the formation of a-synuclein protein, which is associated with the development of Lewy bodies. The study focuses on the role of the prototypical beta-adrenergic agonist epinephrine and its synthetic selective receptor agonist levalbuterol in suppressing neuroinflammation and degeneration of dopaminergic neurons. The findings suggest that these agents may have implications for the treatment of Parkinson's disease, other neurodegenerative syndromes, and malignancies. [Extracted from the article]

A recent preprint abstract suggests that Parkinsonism, a condition characterized by motor dysfunction, can be divided into three molecular subgroups in the fruit fly Drosophila. The study used behavioral screening and machine learning to identify three clusters of mutants that converge on different cellular pathways: mitochondrial function, retromer/vesicle trafficking, and proteostasis/autophagy. The findings indicate that familial Parkinsonism can be stratified into these functional groups, which could lead to targeted biomarker discovery and drug development. However, it is important to note that this research has not yet undergone peer review. [Extracted from the article]

A recent study conducted at PD Hinduja National Hospital in Maharashtra, India, examined the frequency and burden of non-motor symptoms (NMS) in patients with Parkinson's disease (PD) and atypical Parkinsonism (APD). The study found that NMS were common in both PD and APD, with APD patients experiencing a higher frequency and burden of NMS compared to PD patients and healthy controls. Sexual dysfunction was the most commonly reported NMS in both groups, followed by other symptoms such as urinary urgency, fatigue, and constipation. The findings suggest that addressing NMS is important in the management of Parkinsonism syndromes. [Extracted from the article]

A recent study conducted by the Karolinska Institute in Stockholm, Sweden, has investigated the relationship between olfactory dysfunction and Parkinson's disease (PD). The researchers used a mouse model of early-stage PD to replicate the olfactory deficit observed in patients. They found that long-term administration of pramipexole, a dopamine D2/3 selective agonist, improved odor discrimination in the mouse model. The study also revealed that pramipexole normalized dopamine neurons and beta band oscillations in the olfactory bulb, providing insights into the potential mechanisms underlying PD-related olfactory dysfunction. This research sheds light on the treatment possibilities for olfactory dysfunction in PD. [Extracted from the article]

The article presents research from Rush University Medical Center on the progression of parkinsonian signs in relation to Parkinson's disease and Alzheimer's-related dementias. Topics discussed include the impact of cerebrovascular pathologies versus pathological Parkinson's disease, the varying rates of progression across different groups, and the general association between parkinsonism and cerebrovascular issues in older adults.

The article discusses a study on the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease, conducted by Anhui Medical University, published in the journal Clinical Trials Week on August 19, 2024. Topics include the study's aim to improve motor symptoms through targeted stimulation of the supplementary motor area (SMA), the trial's design and outcome measures, and the current recruitment status.

The article discusses research by Ann C. McKee from Boston University and, reported in the JAMA Neurology issue, on August 19, 2024. Topics include the association between contact sports and parkinsonism in individuals with chronic traumatic encephalopathy (CTE), the impact of repetitive head impacts on substantia nigra pathology, and the relationship between nigral neuronal loss and parkinsonism.

A recent report from researchers at Universidade Iguacu in Brazil discusses the case of a 72-year-old woman who initially presented with symptoms of idiopathic Parkinson's disease but later developed dysphagia, dysphonia, quadriparesis, and other neurological symptoms. Further examination revealed the presence of a variant in the PRKAG2 gene, which is associated with cardiac arrhythmia, preexcitation syndromes, hypertrophic cardiomyopathy, motor neuron disease, and parkinsonism. The researchers emphasize the importance of considering PRKAG2 variants in complex clinical scenarios. The full report can be accessed for free online. [Extracted from the article]

A recent report from the Institute of Zoology discusses research on Parkinson's disease and the role of the gut microbiota in its pathogenesis. The study used a non-human primate model to investigate the interaction between the gut microbiota and the host. The researchers identified key genes involved in inflammation, mitochondrial function, neuroprotection, and neurogenesis associated with Parkinson's disease. They also found significant alterations in metabolomic profiles, particularly those related to inflammation, mitochondrial dysfunction, and neurodegeneration. The study provides new insights into the potential role of metabolites in the host-microbiota interaction in Parkinson's disease. [Extracted from the article]

A new report from the Mayo Clinic provides insights into progressive supranuclear palsy (PSP), a neurodegenerative tauopathy with diverse clinical syndromes. The researchers used cross-sectional MRI and FDG-PET scans to identify patterns of brain atrophy and hypometabolism in PSP patients. These patterns were then used to predict specific clinical features and assess their relationship to phenotypic heterogeneity. The study found that MRI predictions were more robust and generalized better to the test set, and that PSP leads to neurodegeneration in motor, cognitive, and ocular motor networks. The researchers emphasize the importance of data-driven approaches to clinical neuroimaging analyses in understanding the heterogeneity of PSP. [Extracted from the article]

A recent study conducted by researchers from the University of Manitoba in Winnipeg, Canada, aimed to determine the impact of specialized care on health outcomes and healthcare utilization in individuals with Parkinsonism (PKM). The study found that movement disorder neurologist care was associated with a lower risk of admission to long-term care (LTC) compared to general neurologist and non-neurologist care. However, there was no significant difference in mortality, emergency visits, hospital admissions, or hospital days between the different providers. This research provides valuable insights into the optimal care for individuals with Parkinsonism. [Extracted from the article]

A recent study conducted by researchers at the Mayo Clinic in Jacksonville, Florida, focused on Progressive Supranuclear Palsy (PSP), a neurodegenerative disease. The study aimed to clarify the clinicopathological features of patients with upper motor neuron-predominant motor neuron disease (MND). The researchers reviewed the medical records of patients with PSP and corticobasal degeneration (CBD) and found that patients with upper motor neuron-predominant MND can mimic atypical parkinsonism, such as CBD and PSP syndrome. The study suggests that this type of MND should be considered in the differential diagnosis of these conditions. [Extracted from the article]

A recent study conducted by researchers at Hebrew University in Jerusalem explores the potential association between chronic liver cirrhosis and Parkinson's disease (PD). The study examined medical records of individuals with PD and chronic liver impairment due to cirrhosis or liver metastases to identify temporal correlations between liver insult and Parkinsonian signs. The findings suggest a clinical association between cirrhosis and PD, and the researchers propose a diagnostic scheme that may guide therapeutic interventions and prognostic assessments. Further research is needed to fully understand the relationship between these two conditions. [Extracted from the article]

A recent study conducted by researchers at the Autonomous University of San Luis Potosi has found that speech samples can be used as a diagnostic tool for Parkinson's disease. The study involved 30 individuals with Parkinson's disease and 30 healthy subjects, who were asked to repeat a syllable sequence under different auditory feedback conditions. The results showed that individuals with Parkinson's disease had difficulties in whispering and articulating under altered auditory feedback conditions, exhibited delayed speech onset, and demonstrated inconsistent rhythmic structure compared to the control group. A machine-learning algorithm was then used to differentiate between the two groups, achieving an accuracy of 85.4%. This pilot study suggests that the proposed behavioral paradigm could be an objective and accessible test for identifying individuals with Parkinson's disease. [Extracted from the article]

Researchers from Sapienza University of Rome have conducted a study on the role of non-invasive brain modulation in identifying disease biomarkers for diagnostic and therapeutic purposes in Parkinsonism. The study explores the advancements in non-invasive brain stimulation techniques, such as transcranial magnetic stimulation (TMS) and transcranial electrical stimulation (TES), and their potential in understanding Parkinson's disease and atypical Parkinsonism. While promising findings have been observed, the integration of these techniques into clinical practice remains a subject of ongoing investigation and scientific debate. The study emphasizes the importance of future research to maximize the efficacy and relevance of non-invasive brain stimulation strategies for individuals with Parkinsonism. [Extracted from the article]

A cross-sectional study of contact sports athletes with chronic traumatic encephalopathy (CTE) found that years of participation in contact sports were associated with substantia nigra tau pathology and neuronal loss. These pathologies were also associated with parkinsonism, suggesting that repetitive head impacts may trigger neuropathologic processes that lead to symptoms of parkinsonism in individuals with CTE. The study highlights the potential long-term consequences of contact sports on brain health. For more information, including author details and funding sources, please refer to the original article. [Extracted from the article]

A study conducted by researchers at Boston University School of Medicine and VA Boston Healthcare has found a link between playing contact sports, chronic traumatic encephalopathy (CTE), and the development of parkinsonism. The study, which examined 481 deceased athletes, revealed that most individuals with CTE developed parkinsonism, and CTE pathology appears to be driving the symptoms. Parkinsonism is characterized by symptoms similar to Parkinson's disease, such as tremors and abnormal slowness of movements. The study also found that individuals with CTE and parkinsonism were more likely to have severe brain cell death in a region of the brainstem important for controlling movement. This study highlights the importance of understanding the long-term effects of repetitive head impacts in contact sports and the need for preventive measures to mitigate the risk of neurodegenerative diseases like CTE and parkinsonism. [Extracted from the article]

Tyler Medical Research LLC has been issued a patent for compositions and methods for treating symptoms in Parkinson's disease patients. The patent describes a pulsatile or extended release dosage form containing nicotine for once or twice-daily administration. The dosage form aims to treat motor symptoms in Parkinson's disease patients, including symptoms associated with treatment. The patent also includes claims for delayed release and extended release dosage forms, as well as a method of treating gait and balance problems in Parkinson's disease patients. [Extracted from the article]

A study conducted by researchers at Shanghai University in China has developed a radiomics-guided deep learning (DL) model to aid in the differential diagnosis of Parkinsonian syndromes. The study recruited 1495 subjects for 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) scanning, including healthy controls and patients diagnosed with idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA), or progressive supranuclear palsy (PSP). The radiomics-guided DL model outperformed the baseline radiomics approach, demonstrating its effectiveness in diagnosing Parkinsonian disorders. The study suggests that the model holds promise for personalized disease monitoring. [Extracted from the article]

Researchers at Anhui University of Chinese Medicine have published a case report on a Chinese female patient with primary familial brain calcification (PFBC) and dopamine-responsive parkinsonism. The patient experienced motor fluctuations and dyskinesia, but effectively recovered after adjusting her medication. Whole-exome sequencing revealed a novel harmful variant in the SLC20A2 gene, expanding the understanding of PFBC and its associated symptoms. The study highlights the clinical efficacy of dopaminergic replacement treatment for PFBC patients. For more information, readers can refer to the article published in Frontiers in Neurology. [Extracted from the article]

A recent study conducted by researchers at Brown University in Providence, Rhode Island, explores the relationship between Alzheimer's disease (AD) and Parkinson's disease (PD). While it is known that advanced cases of AD can lead to parkinsonism, this study presents a rare case of parkinsonism as the initial manifestation of AD. The patient exhibited symptoms consistent with PD for 12 years, including the development of dementia, but further examination revealed AD changes in the brain and no evidence of PD. The researchers suggest that neuronal loss and the presence of neurofibrillary tangles and amyloid plaques likely contributed to the parkinsonism features. This research has been peer-reviewed and provides valuable insights into the complex relationship between AD and PD. [Extracted from the article]

A recent study conducted at the University of Bari in Italy explores the relationship between Parkinson's disease and primary progressive aphasia (PPA). The study focuses on a case of a 63-year-old man who presented with language impairment and early parkinsonism symptoms. The researchers found that the man had a diagnosis of primary progressive logopenic aphasia with amyloid pathology, which coexisted with prominent and early parkinsonism. This case highlights the complex connection between language disorders, parkinsonism, and amyloid pathology in PPA. [Extracted from the article]

A recent study conducted by researchers at the University of California has revealed new findings on Parkinson's disease. The study focused on the quantification of motor symptom progression in Parkinson's disease patients, which is crucial for assessing disease progression and optimizing therapeutic interventions. The researchers developed an interpretable video-based framework that predicts high versus low Parkinson's disease motor symptom severity. This framework utilizes consumer-grade devices such as smartphones and tablets, eliminating the need for specialized equipment. The study provides valuable insights into the clinical analysis of Parkinson's disease and offers a potential solution for objective symptom quantification. [Extracted from the article]

Researchers at the Karolinska Institute in Stockholm, Sweden have conducted a study on Parkinson's disease. The study focused on the degeneration of dopamine neurons in the substantia nigra pars compacta, which leads to motor impairments in Parkinson's patients. The researchers also investigated the alterations in serotonergic and noradrenergic transmission in the dorsal raphe nucleus, a primary locus of serotonergic neurons. They found that the depletion of both noradrenaline and dopamine in a mouse model of Parkinsonism caused changes in the neural circuitry of the dorsal raphe. This research provides insights into the non-motor comorbidities experienced by Parkinson's patients and may contribute to the development of new treatments. [Extracted from the article]

A patent application titled "Method To Identify And Alleviate The Symptoms Of Parkinsonism/Parkinson's Disease" has been published online. The inventors propose a method of treating neurodegenerative disorders by administering a CB1 agonist and a cannabinoid to the patient. The patent application suggests that this treatment could potentially improve motor disorders such as Parkinson's disease and L-DOPA-induced dyskinesia. The inventors recommend the use of Palmidrol as the CB1 agonist and Dronabinol as the cannabinoid, with specific dosage ranges mentioned. This information may be of interest to researchers studying Parkinson's disease and related conditions. [Extracted from the article]

A recent study conducted by researchers at the National University of Cordoba in Argentina explored the potential benefits of insulin-like growth factor 1 (IGF-1) gene therapy in a Parkinsonism model. The study found that IGF-1 gene therapy improved cognitive deficits related to memory and increased expression levels of tyrosine hydroxylase, a protein involved in dopamine production. Additionally, the therapy resulted in significant changes in microglia and astrocyte phenotypes, suggesting a potential link between cognitive function and inflammation. These findings support the use of IGF-1 as a therapeutic molecule for future gene transfer interventions. [Extracted from the article]

A recent study conducted by researchers at the University of Tsukuba in Japan focuses on the detection of freezing of gait (FoG) in patients with Parkinson's disease. FoG is a common symptom in individuals with Parkinson's disease and related disorders. The researchers developed a method to automatically detect FoG from videos taken in uncontrolled environments, such as daily clinical practices. The method combines object tracking, 3D pose estimation, and expert-guided feature selection, achieving a high intraclass correlation coefficient. This novel approach has the potential to improve the detection of FoG in real-world settings. [Extracted from the article]

Population Bio Inc. has been granted a patent for methods of diagnosing, prognosing, and treating Parkinson's disease or parkinsonism. The patent involves screening individuals for genetic variations associated with neurological disorders, such as Parkinson's disease, using various samples like blood, saliva, urine, serum, tears, skin, tissue, or hair. The presence of these genetic variations can indicate whether an individual has the neurological disorder or an increased susceptibility to it. The methods described in the patent utilize techniques like PCR, sequencing, and microarray analysis to detect and analyze the genetic variations. These methods have the potential to aid in the development of therapeutics and improve disease management for neurological disorders. The patent also includes methods for administering therapeutic agents based on specific genetic variations. The patent was filed by Peggy S. Eis and published in June 2024. [Extracted from the article]

A recent study has found that mutations in the EPG5 gene are associated with a wide range of neurodevelopmental and neurodegenerative disorders. The study examined the genetic, clinical, neuroradiological, and pathological features of the largest cohort of EPG5-related disorders to date. The associated phenotypic spectrum varied from severe multisystem neurodevelopmental disorders to milder neurodevelopmental disorders with less specific manifestations. The study also found a correlation between predicted residual EPG5 expression and clinical severity. These findings suggest a continuum of disease that overlaps with other disorders of defective autophagy and intracellular trafficking, highlighting the importance of dysfunctional autophagy in the pathophysiology of common neurodegenerative disorders. [Extracted from the article]

A patent has been issued for 9H-pyrrolo-dipyridine derivatives by Ucb Biopharma Srl. The invention relates to these derivatives as imaging agents for the detection of Tau aggregates in the brain, which are associated with neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy. The compounds have high binding to Tau aggregates and low non-specific binding, making them suitable for accurate diagnosis and monitoring of treatment effects. The patent also includes methods for diagnosing or monitoring Tau aggregates and treating neurodegenerative diseases. [Extracted from the article]

Researchers from Harvard University Medical School have conducted a study on X-linked dystonia parkinsonism (XDP), a neurogenetic movement disorder that involves both parkinsonism and dystonia. The study aimed to assess the feasibility of using wearable sensor data to quantify the clinical severity of XDP. The researchers collected sensor data from 10 XDP patients and 3 healthy controls during a standardized examination and used machine learning algorithms to estimate clinical scores. The study found that wearable sensor data could provide reliable estimates of clinical scores associated with both parkinsonian and dystonic features in XDP patients. The findings suggest the potential utility of motion sensors in quantifying clinical examination in complex movement disorders. [Extracted from the article]

This document provides information about a clinical trial, NCT06438419, that is being conducted in France by the University Hospital, Bordeaux. The trial aims to study the effects of different conditions, including pharmacological treatment and stimulation, on electrophysiological recordings during a motor task in patients with Parkinson's disease. The trial is not yet recruiting and is expected to enroll 20 participants, with an estimated completion date of June 2026. To be eligible for the trial, participants must be between 18 and 75 years old, have idiopathic Parkinson's disease, and be able to perform a simple motor task. The primary purpose of the trial is basic science research. [Extracted from the article]

A patent application has been filed for methods and compositions to treat conditions associated with nucleotide repeat expansion, such as Fragile X syndrome, Parkinson's disease, and Huntington's disease. The application describes using an inactive Cas9 protein and a guide RNA to reduce the number of nucleotide repeats in cells, potentially restoring gene function. These methods and compositions have the potential to be used in the treatment of various neurodevelopmental and neurodegenerative disorders. Currently, there are no cures for these diseases, and treatments are limited to managing symptoms. [Extracted from the article]

A recent study conducted at the University 'Magna Graecia' Catanzaro in Italy explored the cognitive profile of individuals with Atypical Parkinsonism (AP) syndromes. The study compared the cognitive functioning of AP patients to healthy controls and patients with Parkinson's Disease (PD). The findings revealed that patients with AP exhibited significant cognitive impairment across various domains compared to healthy controls. The study suggests that widespread cognitive impairment could serve as a valuable clinical indicator to differentiate AP from other movement disorders. [Extracted from the article]

A recent systematic review conducted by researchers at the University of Texas Health Science Center Houston explores the rare occurrence of intracranial dural arteriovenous fistulas (IDAVFs) presenting with both parkinsonism and dementia. The review analyzed 33 articles, including case reports and case series, which described a total of 43 patients with IDAVFs presenting with both parkinsonism and dementia. The study found that the anatomical distribution of IDAVFs varied, with the transverse and sigmoid sinuses being the most common locations. While most patients received endovascular therapy, some underwent microsurgical occlusion or combined surgical and endovascular treatment. The researchers concluded that further research involving larger cohorts is necessary to better understand the underlying mechanisms and establish standardized therapeutic guidelines. [Extracted from the article]

According to a preprint abstract, a study has found that decreased excitability of pyramidal tract neurons in the primary motor cortex can lead to increased network activity in simulated parkinsonian motor cortex. The study used computer simulations and found that the decrease in excitability resulted in an increase in rest-state firing rate and beta-band oscillatory power in local field potential. This increase in network activity may contribute to motor activity deficits seen in patients with Parkinson's disease. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A new report from Bristol, United Kingdom discusses the under-representation of older individuals with parkinsonism, frailty, multimorbidity, or impaired capacity to consent in research on Parkinson's disease. The researchers aimed to evaluate more inclusive recruitment strategies and found that more intensive engagement enhanced recruitment of women, care home residents, patients with atypical parkinsonism, and those with higher frailty scores. These strategies resulted in a less biased and more representative sample, including older people with more complex parkinsonism. The study was supported by various organizations and can be found in the journal Age and Ageing. [Extracted from the article]

A report from researchers at Kaohsiung Medical University in Taiwan discusses a case of acute parkinsonism in a 66-year-old woman who had been consuming black pills, a type of traditional Chinese medicine obtained from an unauthorized source. The patient experienced symptoms such as frequent falls, unsteady gait, and slow movements, which led to a diagnosis of parkinsonism. Laboratory tests revealed elevated blood mercury levels, and imaging studies confirmed dysfunction in the putamina, consistent with secondary parkinsonism. Treatment with chelation therapy resulted in significant symptom improvement. The report emphasizes the importance of a thorough drug history and toxicology assessment in cases of acute parkinsonism and highlights the need for timely intervention. [Extracted from the article]

A recent report from researchers at the University of Oxford discusses the findings of a study on retinal morphological differences in atypical Parkinsonism. Atypical Parkinsonian syndrome (APS) is a group of disorders that mimic the clinical presentation of Parkinson's disease (PD) but have different natural history and pathophysiology. The study analyzed data from the AlzEye cohort, which included ophthalmic data from patients attending Moorfields Eye Hospital. The researchers found that individuals with APS had a thinner ganglion cell-inner plexiform layer in the retina compared to healthy controls, but no significant differences in other retinal features. These findings suggest that retinal imaging could be a valuable tool for diagnosing and differentiating neurodegenerative disorders. [Extracted from the article]

A recent study conducted by researchers at Iowa State University explored the neurotoxic effects of co-exposure to manganese (Mn) and vanadium (V) in an animal model. The study found that chronic exposure to these heavy metals, which often occurs through occupational and industrial sources, can lead to severe neurotoxicity in the olfactory system. The co-exposure of Mn and V resulted in significant decreases in olfactory bulb weight and levels of certain neurotransmitters, as well as increased expression of a-synuclein in the substantia nigra. The findings suggest that environmental metal mixtures may play a role in the development of Parkinsonism. [Extracted from the article]

A patent application titled "Induced Expression of Brain Derived Neurotrophic Factor (BDNF) for Treatment of Neuromuscular, Neurodegenerative, Autoimmune, Developmental and/or Metabolic Diseases" has been published by the US Patent and Trademark Office. The application, filed by Robert Alonso and John Geisler and assigned to Mitochon Pharmaceuticals Inc., discusses the use of 2,4-dinitrophenol (DNP) to increase the expression of BDNF, a protein involved in neuronal development. The method aims to treat diseases such as Alzheimer's, Parkinson's, epilepsy, multiple sclerosis, and autism by increasing BDNF levels. The effective dose of DNP ranges from 0.001 mg/kg to less than 10 mg/kg of body weight, and the pharmaceutical composition can be administered orally, intravenously, or through other methods. The patent application also includes unit doses and dosage forms for the composition. [Extracted from the article]

According to a preprint abstract, researchers have investigated the effects of injecting tetanus neurotoxin (TeNT) into different regions of the basal ganglia in rats. They found that TeNT induced temporary motor dysfunctions consistent with experimental parkinsonism, with specific symptoms depending on the targeted region. The study suggests that TeNT could be a useful pharmacological agent for studying motor control abnormalities involving GABA-ergic basal ganglia circuits. However, it is important to note that this research has not yet undergone peer review. [Extracted from the article]